CRIMM Centro Ricerca e Innovazione delle Malattie Mieloproliferative croniche

Firenze, Italy

CRIMM Centro Ricerca e Innovazione delle Malattie Mieloproliferative croniche

Firenze, Italy
SEARCH FILTERS
Time filter
Source Type

Guglielmelli P.,CRIMM Centro Ricerca e Innovazione delle Malattie Mieloproliferative croniche | Guglielmelli P.,University of Florence | Rotunno G.,CRIMM Centro Ricerca e Innovazione delle Malattie Mieloproliferative croniche | Rotunno G.,University of Florence | And 4 more authors.
Current Hematologic Malignancy Reports | Year: 2015

The molecular landscape of patients with myelofibrosis (MF) includes “phenotypic driver” and “subclonal” mutations. The three driver (JAK2, MPL and CALR)-mutated genes currently represent major diagnostic criteria, unlike subclonal mutations that are not specific for the disease and occur in other myeloid neoplasms. Recent data indicate that selected mutations deserve prognostic significance allowing to identify categories of patients with different survival and risk of leukemia. This review focuses on current knowledge regarding genotype-prognostic correlates in MF, however, with the understanding that this is a rapid moving field and no definite recommendations for the clinicians can be done yet. © 2015, Springer Science+Business Media New York.


PubMed | CRIMM Centro Ricerca e Innovazione delle Malattie Mieloproliferative croniche
Type: Journal Article | Journal: Current hematologic malignancy reports | Year: 2015

The molecular landscape of patients with myelofibrosis (MF) includes phenotypic driver and subclonal mutations. The three driver (JAK2, MPL and CALR)-mutated genes currently represent major diagnostic criteria, unlike subclonal mutations that are not specific for the disease and occur in other myeloid neoplasms. Recent data indicate that selected mutations deserve prognostic significance allowing to identify categories of patients with different survival and risk of leukemia. This review focuses on current knowledge regarding genotype-prognostic correlates in MF, however, with the understanding that this is a rapid moving field and no definite recommendations for the clinicians can be done yet.

Loading CRIMM Centro Ricerca e Innovazione delle Malattie Mieloproliferative croniche collaborators
Loading CRIMM Centro Ricerca e Innovazione delle Malattie Mieloproliferative croniche collaborators